Akorn gets FDA nod for betamethasone dipropionate lotion USP
LAKE FOREST, Ill. — Akorn, a leading specialty pharmaceutical company, Monday announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (Augmented), 0.05%. The product is manufactured at Akorn’s Amityville, N.Y. manufacturing facility.According to IQVIA, U.S. sales of betamethasone dipropionate
